Organizational theorists have had much to say about how environments affect organizations but have said relatively little about how organizations shape their environment. This silence is particularly troubling, given that organizations, in general, and corporations, in particular, now wield inordinate political power. This article illustrates three ways in which corporations can undermine representative democracy and the public good: promoting legislation that benefits corporations at the expense of individual citizens, the capturing of regulatory agencies by those whom the agencies were designed to regulate, and the privatization of functions that have historically been the mandate of local, state, and federal governments.
Amnesty International. (2006). Annual report: Outsourcing facilitating human rights violations. Retrieved August 2006 from http://www.amnestyusa.org/annualreport/2006/overview.html
2.
Bakan, J. (2004). The corporation: The pathological pursuit of profit and power. New York: Free Press .
3.
Bierce, A. (1999). The devil's dictionary. New York: Oxford University Press. (Original work published 1911)
4.
Dreyfuss, R. (1997). Popping contributions: The new battle for the FDA. The American Prospect, pp. 53-59.
5.
Hartmann, T. (2002). Unequal protection: The rise of corporate dominance and the theft of human rights. New York: Rodale.
6.
Hickson, D.J., Hinings, C.R., Lee, C.A., Schneck, R.E., & Pennings, J.M. (1971). A strategic contingencies' theory of interorganizational power. Administrative Science Quarterly,16, 216-229.
7.
Himmelstein, D.U., Warren, E., Thorne, D., & Woolhandler, S. (2005). Illness and injury as contributors to bankruptcy. Health Affairs, 24, 63-73.
Jacoby, M.B., Sullivan, T.A., & Warren, E. (2001). Rethinking the debates over health care financing: Evidence from the bankruptcy courts. New York UniversityLaw Review, 76(2), 375-218.
10.
Jensen, S. (2005). A legislative history of the Bankruptcy Abuse Prevention and Consumer Protection Act of 2005. American Bankruptcy Law Journal, 79, 485-569.
11.
Kuhlik, B.N. (1992). Industry funding of improvements in the FDA's new drug approval process: The Prescription Drug User Fee Act of 1992. Food and Drug Law Journal, 47, 483-503.
12.
Markey, E.J. (2005). Conspiracy of silence: How the FDA allows drug companies to abuse the accelerated approval process. Washington, DC: Congressional Printing Office.
13.
Nace, T. (2003). Gangs of America: The rise of corporate power and the disabling of democracy. San Francisco: Berrett-Koehler.
14.
Olson, M.K. (2000). Regulatory reform and bureaucratic responsiveness to firms: The impact of user fees in the FDA. Journal of Economics and Management Strategy, 9, 363-395.
15.
Olson, M.K. (2002a). How have user fees affected the FDA?Regulation, 25, 20-25.
16.
Olson, M.K. (2002b). Pharmaceutical policy change and the safety of new drugs. Journal of Law and Economics, 45, 615-642.
17.
Olson, M.K. (2004a). Are novel drugs more risky for patients than less novel drugs?Journal of Health Economics, 23, 1154-1158.
18.
Olson, M.K. (2004b). Managing delegation in the FDA: Reducing delay in new-drug review. Journal of Health Politics, Policy and Law, 29, 397-430.
19.
Perrow, C. (2002). Organizing America: Wealth, power and the origins of corporate capitalism. Princeton, NJ: Princeton University Press.
20.
Pfeffer, J., & Salancik, G.R. (1978). The external control of organizations: A resource dependence perspective. New York : Harper & Row.
21.
Prechel, H. (2000). Big business and the state: Historical transitions and corporate transformation, 1880s-1990s. Albany: SUNY Press.
22.
Santa Clara County v. Southern Pacific Railroad Co., 118 U.S. 394 (1886).
23.
Simpson, J., & Weiner, E. (Eds.). (1989). Oxford English dictionary (2nd ed.). Oxford, UK: Clarendon.
24.
Singer, P.W. (2003). Corporate warriors: The rise of the privatized military industry. Ithaca, NY: Cornell University Press.
25.
Singer, P.W. (2004). Warriors for hire in Iraq. Retrieved August3, 2006, from http://dir.salon.com/story/news/feature/2004/04/15/warriors/index.html
26.
Stern, R.N., & Barley, S.R. (1996). Organizations and social systems: Organization theory's neglected mandate. Administrative Science Quarterly,41, 146-162.
27.
Sullivan, T.A., Warren, E., & Westbrook, J. (2001). The fragile middle class: Americans in debt. New Haven, CT: Yale University Press.
28.
Timmerman, L. (2002). FDA to boost its user fees: Drug industry cash will add regulatory staffing The Seattle Times, p. 2.
29.
U.S. Food and Drug Administration. (2005a). FDA history. Retrieved August 2005 from http://www.fda.gov/oc/history/default.htm
30.
U.S. Food and Drug Administration. (2005b). Mission. Retrieved August 2005 from http://www.fda.gov/opacom/morechoices/mission.html
31.
U.S. General Accounting Office. (2002). Food and Drug Administration: Effect of user fees on drug approval times, withdrawals and other agency activities. Washington, DC : Government Printing Office.
32.
Warren, E. (1998). The bankruptcy crisis. Indiana Law Journal, 73, 1079-1094.
33.
Willman, D. (2000). FDA drug approvals reexamined. ContraCosta Times, p. 10.
34.
Woolley, J., & Peters, G. (2005). The American presidency project, Andrew Jackson, fifth annual message. Retrieved August 2005 from http://www.presidency.ucsb.edu/ws/index.php?pid=29475
